Phenylephrine (diagnostic)
Dilation & diagnostic · Rx
RxDilation & diagnosticMydriatic Red cap
| Strength | 2.5%, 10% |
|---|---|
| Drug class | Alpha-1 adrenergic mydriatic (no cycloplegia) |
| Mechanism of action | Alpha-1 agonist; contracts the iris dilator muscle. Produces mydriasis without cycloplegia; also blanches conjunctival vessels. |
| Indication / reason for use | Adjunct to an anticholinergic for fuller dilation; differentiating episcleritis (blanches) from scleritis (does not); breaking recent posterior synechiae (with an anticholinergic); pre-operative dilation. |
| Usual adult dosing | 1 drop of 2.5% (combine with tropicamide). Onset ~20 min. |
| Preservative | BAK |
| Contact lenses | Remove lenses; reinsert after 15 minutes. |
| Common / important adverse effects | 10% strength: significant systemic hypertension, reflex bradycardia, arrhythmia, and rare MI/stroke reported, avoid 10% in infants, the elderly, and cardiovascular disease. Rebound miosis and lid retraction. Stinging. |
| Contraindications & cautions | 10% in infants, elderly, hypertension, cardiovascular disease, aneurysm, thyrotoxicosis, on MAOIs/tricyclics/atomoxetine. Narrow angles (relative). |
| Pregnancy / lactation | Avoid the 10% strength; 2.5% single diagnostic dose with punctal occlusion is generally acceptable. |
| Trade names | Mydfrin 2.5%, Neo-Synephrine Ophthalmic 2.5% / 10% |
| Practice notes | Use 2.5%, there is almost no diagnostic reason to reach for 10%. |
Chair-side reference only. Dosing, contraindications and pregnancy guidance here are not exhaustive. Confirm against the current prescribing information and the patient’s full history before prescribing or advising.